Checkpoint Therapeutics Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Checkpoint Therapeutics de 88.1% y 79.6% respectivamente, mientras que el BPA crecerá en un 91.7% al año.
Información clave
88.1%
Tasa de crecimiento de los beneficios
91.7%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 23.2% |
| Tasa de crecimiento de los ingresos | 79.6% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 25 Mar 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Sep 20
Checkpoint: Strong Data, But Comes With Risks
Sep 08Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M
Aug 12Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?
May 18Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Apr 18Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Feb 15Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results
Jan 28Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout
Nov 26Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans
Oct 30We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Jul 17Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
Jul 14Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow
Jun 21Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential
Jun 09It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year
Jun 02The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It
Mar 11Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?
Feb 06
Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?
Jan 27Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Dec 23What We Learned About Checkpoint Therapeutics' (NASDAQ:CKPT) CEO Pay
Nov 27Checkpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung Biologics
Nov 02Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 96 | N/A | 30 | N/A | 1 |
| 12/31/2025 | 172 | 61 | -22 | N/A | 2 |
| 12/31/2024 | 1 | -52 | -59 | N/A | 4 |
| 12/31/2023 | 0 | -52 | -48 | -48 | N/A |
| 9/30/2023 | 0 | -54 | -56 | -56 | N/A |
| 6/30/2023 | 0 | -59 | -53 | -53 | N/A |
| 3/31/2023 | 0 | -56 | -52 | -52 | N/A |
| 12/31/2022 | 0 | -63 | -58 | -58 | N/A |
| 9/30/2022 | 0 | -71 | -52 | -52 | N/A |
| 6/30/2022 | 0 | -72 | -47 | -47 | N/A |
| 3/31/2022 | 0 | -67 | -41 | -41 | N/A |
| 12/31/2021 | 0 | -57 | -26 | -26 | N/A |
| 9/30/2021 | 0 | -37 | -22 | -22 | N/A |
| 6/30/2021 | 0 | -31 | -20 | -20 | N/A |
| 3/31/2021 | 0 | -26 | -17 | -17 | N/A |
| 12/31/2020 | 1 | -23 | -17 | -17 | N/A |
| 9/30/2020 | 1 | -22 | -16 | -16 | N/A |
| 6/30/2020 | 1 | -22 | -15 | -15 | N/A |
| 3/31/2020 | 2 | -22 | -18 | -18 | N/A |
| 12/31/2019 | 2 | -25 | -21 | -21 | N/A |
| 9/30/2019 | 5 | -28 | -24 | -24 | N/A |
| 6/30/2019 | 4 | -32 | -27 | -27 | N/A |
| 3/31/2019 | 4 | -33 | -29 | -29 | N/A |
| 12/31/2018 | 4 | -36 | -26 | -26 | N/A |
| 9/30/2018 | 1 | -31 | -22 | -22 | N/A |
| 6/30/2018 | 1 | -27 | -20 | -20 | N/A |
| 3/31/2018 | 1 | -27 | -18 | -18 | N/A |
| 12/31/2017 | 2 | -23 | -16 | -15 | N/A |
| 9/30/2017 | 2 | -25 | N/A | -15 | N/A |
| 6/30/2017 | 2 | -24 | N/A | -14 | N/A |
| 3/31/2017 | 3 | -23 | N/A | -11 | N/A |
| 12/31/2016 | 3 | -22 | N/A | -10 | N/A |
| 9/30/2016 | 2 | -22 | N/A | -7 | N/A |
| 6/30/2016 | 2 | -21 | N/A | -7 | N/A |
| 3/31/2016 | 0 | -16 | N/A | -5 | N/A |
| 12/31/2015 | 1 | -14 | N/A | -1 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que CKPT sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Se prevé que CKPT sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que CKPT sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (79.6% al año) de CKPT crezcan más rápidamente que los del mercado US (8.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (79.6% al año) de CKPT crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CKPT se prevé que sea elevada dentro de 3 años.